Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,266.95 -39.09 (-0.74%) Dow
38,441.54 -411.32 (-1.06%) Nasdaq
16,920.58 -99.30 (-0.58%) Bitcoin USD
67,667.12 -628.13 (-0.92%) CMC Crypto 200
1,452.67 -32.02 (-2.16%)
JNJ Oct 2024 195.000 call
| Previous close | 0.1500 |
| Open | 0.1500 |
| Bid | 0.0200 |
| Ask | 1.3300 |
| Strike | 195.00 |
| Expiry date | 2024-10-18 |
| Day's range | 0.1500 - 0.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 18 |
PR NewswireSarepta Therapeutics Set to Join S&P MidCap 400
Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
BenzingaJohnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial
Wednesday, Johnson & Johnson (NYSE:JNJ) announced topline results from Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of seltorexant as an adjunctive treatment to baseline antidepressants in adult and elderly patients with major depressive disorder (MDD) with insomnia symptoms. Seltorexant is an investigational first-in-class selective antagonist of the human orexin-2 receptor being studied for the adjunctive treatment of MDD with insomnia symptoms. Also Read: Johnson & Johnso
ZacksAre You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
